



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



B022

Cat. No.:	HY-120501
CAS No.:	1202764-53-1
Molecular Formula:	C ₁₉ H ₁₆ ClN ₅ OS
Molecular Weight:	397.88
Target:	NF-κB
Pathway:	NF-κB
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months



SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (628.33 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		2.5133 mL	12.5666 mL	25.1332 mL
		5 mM		0.5027 mL	2.5133 mL	5.0266 mL
		10 mM		0.2513 mL	1.2567 mL	2.5133 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.23 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (5.23 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	B022 is a potent and selective NF-κB-inducing kinase (NIK) inhibitor (K _i of 4.2 nM; IC ₅₀ =15.1 nM). B022 protects liver from toxin-induced inflammation, oxidative stress, and injury ^{[1][2]} . B022 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAC) with molecules containing Azide groups.
IC ₅₀ & Target	Ki: 4.2 nM (NF-κB-inducing kinase (NIK)) ^[1]
In Vitro	B022 (0-5 μM; 12 hours; Hepa1 cells) treatment suppresses NIK-induced p52 formation in a dose-dependent manner ^[1] . ?B022 (0-5 μM; 12 hours; Hepa1 cells) treatment for 8 h completely blocks NIK-induced expression of TNF-α, IL-6, iNOS, CCL2, and CXCL5 ^[1] . ?B022 prevents NIK- or H2O2-induced β cell death and also ameliorates streptozotocin (STZ)-induced β cell death and

hyperglycemia^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	Hepa1 cells
Concentration:	0 μ M, 0.5 μ M, 5 μ M
Incubation Time:	12 hours
Result:	Suppressed NIK-induced p52 formation in a dose-dependent manner.

RT-PCR^[1]

Cell Line:	Hepa1 cells
Concentration:	0 μ M, 0.5 μ M, 5 μ M
Incubation Time:	12 hours
Result:	Dose-dependently blocked NIK-induced expression of chemokines, cytokines, and iNOS in these cells. Completely blocked NIK-induced expression of TNF- α , IL-6, iNOS, CCL2, and CXCL5.

In Vivo

B022 (30 mg/kg; intravenous injection; twice a day; for 10 days; STOP-NIK male mice) treatment inhibits NIK-triggered liver inflammation and injury in STOP-NIK mice infected with cre adenoviruses^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	STOP-NIK male mice (8 weeks) infected with Ad-cre ^[1]
Dosage:	30 mg/kg
Administration:	Intravenous injection; twice a day; for 10 days
Result:	Completely prevents the lethal effect of abnormally high levels of hepatic NIK in mice. Inhibited the majority of the deteriorating effects of aberrant activation of hepatic NIK.

CUSTOMER VALIDATION

- Nat Commun. 2022 Dec 16;13(1):7782.
- Nat Commun. 2022 Nov 12;13(1):6881.
- Biochim Biophys Acta Mol Basis Dis. 2024 Feb 11;1870(4):167066.
- Int J Pharm. 2022 Nov 1;122361.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Ren X, et al. A small-molecule inhibitor of NF- κ B-inducing kinase (NIK) protects liver from toxin-induced inflammation, oxidative stress, and injury. FASEB J. 2017 Feb;31(2):711-718.
- [2]. Li Z, et al. Discovery of a Potent and Selective NF- κ B-Inducing Kinase (NIK) Inhibitor That Has Anti-inflammatory Effects in Vitro and in Vivo. J Med Chem.

2020;63(8):4388-4407.

[3]. Li X, et al. Activation of NF- κ B-Inducing Kinase in Islet β Cells Causes β Cell Failure and Diabetes. Mol Ther. 2020;28(11):2430-2441.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA